289 related articles for article (PubMed ID: 27699576)
21. Efficacy of bortezomib in systemic extramedullary localizations of multiple myeloma.
Federico V; Breccia M; Petrucci MT; Loglisci G; Mansueto G; Mercanti C; Levi A; Cartoni C; Musto P; Alimena G
Clin Adv Hematol Oncol; 2012 Apr; 10(4):266-8. PubMed ID: 22706491
[No Abstract] [Full Text] [Related]
22. Halting pro-survival autophagy by TGFβ inhibition in bone marrow fibroblasts overcomes bortezomib resistance in multiple myeloma patients.
Frassanito MA; De Veirman K; Desantis V; Di Marzo L; Vergara D; Ruggieri S; Annese T; Nico B; Menu E; Catacchio I; Ria R; Racanelli V; Maffia M; Angelucci E; Derudas D; Fumarulo R; Dammacco F; Ribatti D; Vanderkerken K; Vacca A
Leukemia; 2016 Mar; 30(3):640-8. PubMed ID: 26487273
[TBL] [Abstract][Full Text] [Related]
23. [Kinetic characteristics of tumor growth in multiple myeloma].
Golenkov AK; Kasatkina VV; Kozinets GI; Zlatkina AR
Gematol Transfuziol; 1988 Dec; 33(12):34-6. PubMed ID: 3234732
[No Abstract] [Full Text] [Related]
24. Cutaneous plasmacytomas in myeloma. Relationship to tumor cell burden.
Alberts DS; Lynch P
Arch Dermatol; 1978 Dec; 114(12):1784-7. PubMed ID: 736585
[TBL] [Abstract][Full Text] [Related]
25. Multiple myeloma with skin involvement.
Güvenç B; Canataroğlu A; Gümürdülü Y; Gümürdülü D; Paydaşt S
J Eur Acad Dermatol Venereol; 2001 Jul; 15(4):328-9. PubMed ID: 11730044
[TBL] [Abstract][Full Text] [Related]
26. Hepatic and renal plasma cell lesions in a patient with multiple myeloma in hematological remission.
Galani Z; Viniou N; Kyrtsonis MC; Sachanas S; Antoniou T; Dimopoulou MN; Vassilakopoulos TP; Korkolopoulou P; Nakopoulou L; Patsouris E; Pangalis GA
Anticancer Res; 2007; 27(1B):571-4. PubMed ID: 17348443
[TBL] [Abstract][Full Text] [Related]
27. [Development of an extramedullary plasmacytoma despite disappearing M protein in multiple myeloma by bortezomib treatment].
Koiso H; Tahara K; Osaki Y; Mawatari M; Sekigami T; Yokohama A; Saitoh T; Uchiumi H; Handa H; Tsukamoto N; Karasawa M; Nojima Y; Murakami H
Rinsho Ketsueki; 2009 Feb; 50(2):78-82. PubMed ID: 19265298
[TBL] [Abstract][Full Text] [Related]
28. Unusual discordant responses in two multiple myeloma patients during bortezomib treatment.
Pirrotta MT; Gozzetti A; Cerase A; Bucalossi A; Bocchia M; Defina M; Lauria F
Onkologie; 2008 Feb; 31(1-2):45-7. PubMed ID: 18268398
[TBL] [Abstract][Full Text] [Related]
29. Multiple myeloma.
Singhal S; Mehta J
Clin J Am Soc Nephrol; 2006 Nov; 1(6):1322-30. PubMed ID: 17699365
[TBL] [Abstract][Full Text] [Related]
30. Cutaneous manifestations of multiple myeloma and other plasma cell proliferative disorders.
Bhutani M; Shahid Z; Schnebelen A; Alapat D; Usmani SZ
Semin Oncol; 2016 Jun; 43(3):395-400. PubMed ID: 27178694
[TBL] [Abstract][Full Text] [Related]
31. Cutaneous involvement in multiple myeloma: a clinicopathologic, immunohistochemical, and cytogenetic study of 8 cases.
Requena L; Kutzner H; Palmedo G; Calonje E; Requena C; Pérez G; Pastor MA; Sangueza OP
Arch Dermatol; 2003 Apr; 139(4):475-86. PubMed ID: 12707095
[TBL] [Abstract][Full Text] [Related]
32. Tumor-primed natural killer cells from patients with multiple myeloma lyse autologous, NK-resistant, bone marrow-derived malignant plasma cells.
Katodritou E; Terpos E; North J; Kottaridis P; Verrou E; Gastari V; Chadjiaggelidou C; Sivakumaran S; Jide-Banwo S; Tsirogianni M; Kapetanos D; Zervas K; Lowdell MW
Am J Hematol; 2011 Dec; 86(12):967-73. PubMed ID: 21919039
[TBL] [Abstract][Full Text] [Related]
33. Cutaneous involvement in multiple myeloma and bortezomib.
Siniscalchi A; Fratoni S; Santeusanio G; Del Poeta G; de Fabritiis P; Caravita T
Ann Hematol; 2009 Nov; 88(11):1137-9. PubMed ID: 19259673
[No Abstract] [Full Text] [Related]
34. Multiple myeloma with extramedullary disease.
Oriol A
Adv Ther; 2011 Nov; 28 Suppl 7():1-6. PubMed ID: 22105527
[TBL] [Abstract][Full Text] [Related]
35. Cutaneous Nodules in Multiple Myeloma. Cutaneous plasmacytoma associated with multiple myeloma.
Gómez-Armayones S; Climent F; Servitje O
Actas Dermosifiliogr; 2015 Sep; 106(7):581-2. PubMed ID: 25935193
[No Abstract] [Full Text] [Related]
36. Extramedullary plasmacytoma presenting as a primary mass in the breast. A case report.
Vera-Alvarez J; Marigil-Gómez M; García-Prats MD; Abascal-Agorreta M; López-López JI; Perez-Ruiz J
Acta Cytol; 2003; 47(6):1107-10. PubMed ID: 14674091
[TBL] [Abstract][Full Text] [Related]
37. [Multiple myeloma with cutaneous involvement in a patient with long-standing MGUS].
Giraldo MP; Delgado MP; Rubio Félix D
Sangre (Barc); 1993 Apr; 38(2):156-7. PubMed ID: 8516731
[No Abstract] [Full Text] [Related]
38. [Not Available].
Hitz F
Praxis (Bern 1994); 2016; 105(21):1255-1260. PubMed ID: 28573955
[No Abstract] [Full Text] [Related]
39. Bortezomib-induced pro-inflammatory macrophages as a potential factor limiting anti-tumour efficacy.
Beyar-Katz O; Magidey K; Ben-Tsedek N; Alishekevitz D; Timaner M; Miller V; Lindzen M; Yarden Y; Avivi I; Shaked Y
J Pathol; 2016 Jul; 239(3):262-73. PubMed ID: 27037906
[TBL] [Abstract][Full Text] [Related]
40. Secondary cutaneous plasmacytoma.
Cavo M; Gobbi M; Ghetti P; Patrizi A; Pileri S; Varotti C
Acta Haematol; 1983; 69(4):287-8. PubMed ID: 6402885
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
